Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SIBYL E WRAY

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1881662591
CMS profile
357387
Location
KNOXVILLE, TN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$137,842.56

216 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

By paying entity

PY2019 · entire year · sorted by reported total

Page 4 of 5; records 151–200 of 216 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SIBYL E WRAY

NPI 1881662591 · CMS profile ID 357387

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

KNOXVILLE, TN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 4 of 5; records 151–200 of 216 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1881662591?year=2019&recipient=provider&page=4#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SIBYL E WRAY, NPI 1881662591, CMS profile ID 357387. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 5; records 151–200 of 216 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1881662591?year=2019&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). SIBYL E WRAY, NPI 1881662591, CMS profile ID 357387. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 5; records 151–200 of 216 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1881662591?year=2019&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
SIBYL E WRAY, NPI 1881662591, CMS profile ID 357387, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 5; records 151–200 of 216 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1881662591?year=2019&recipient=provider&page=4#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

216 matching records · $137,842.56 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 216 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 151–200 of 216.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
EMD Serono, Inc. $49.9404/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 702959693 CMS
EMD Serono, Inc. $27.2604/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 702964773 CMS
EMD Serono, Inc. $27.2604/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 702964809 CMS
Novartis Pharmaceuticals Corporation $16.4304/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 660180417 CMS
Avanir Pharmaceuticals, Inc. $22.7704/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 653612597 CMS
Biogen, Inc. $20.0504/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 660661941 CMS
EMD Serono, Inc. $19.3104/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 702974807 CMS
Genentech USA, Inc. $513.0604/16/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681267073 CMS
Genentech USA, Inc. $4,040.0004/16/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681268777 CMS
Genentech USA, Inc. $28.5704/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681317471 CMS
Novartis Pharmaceuticals Corporation $13.3604/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 660180411 CMS
Biogen, Inc. $88.7504/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 660661933 CMS
GENZYME CORPORATION $17.4404/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693935415 CMS
F. Hoffmann-La Roche AG $361.7803/31/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681075535 CMS
Genentech USA, Inc. $17.1203/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681285797 CMS
Novartis Pharmaceuticals Corporation $15.0403/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 660180437 CMS
Teva Pharmaceuticals USA, Inc. $15.5403/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697696723 CMS
GENZYME CORPORATION $22.7403/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693934493 CMS
Amgen Inc. $19.1203/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 663049941 CMS
ASSERTIO THERAPEUTICS, Inc. $15.0103/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681455323 CMS
Genentech USA, Inc. $4,040.0003/19/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681188150 CMS
Genentech USA, Inc. $988.9903/19/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681269747 CMS
Genentech USA, Inc. $23.3203/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681290629 CMS
Biogen, Inc. $15.8403/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 660661939 CMS
Avanir Pharmaceuticals, Inc. $21.9803/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 653612595 CMS
GENZYME CORPORATION $7.0003/13/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693963995 CMS
GENZYME CORPORATION $21.0003/13/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693963999 CMS
GENZYME CORPORATION $1,145.7103/13/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694281607 CMS
Supernus Pharmaceuticals, Inc. $17.9903/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 702370303 CMS
Biogen, Inc. $11.8803/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 660661957 CMS
Biogen, Inc. $3,150.0003/05/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 660661959 CMS
GENZYME CORPORATION $11.0802/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693944933 CMS
GENZYME CORPORATION $110.1402/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693945365 CMS
GENZYME CORPORATION $2,818.0002/27/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693945367 CMS
GENZYME CORPORATION $4,655.0002/27/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693960663 CMS
GENZYME CORPORATION $1,764.4302/27/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693960667 CMS
GENZYME CORPORATION $15.9902/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693992207 CMS
GENZYME CORPORATION $42.0902/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693944973 CMS
GENZYME CORPORATION $2,573.0002/21/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693944975 CMS
GENZYME CORPORATION $2,818.0002/20/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693945071 CMS
GENZYME CORPORATION $416.3302/20/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693945073 CMS
GENZYME CORPORATION $226.8302/20/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693945075 CMS
GENZYME CORPORATION $4,410.0002/20/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693946727 CMS
GENZYME CORPORATION $22.5502/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694274255 CMS
GENZYME CORPORATION $114.5102/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694277833 CMS
Biogen, Inc. $9,450.0002/14/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 660661885 CMS
ACADIA Pharmaceuticals Inc $12.8402/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700028499 CMS
Novartis Pharmaceuticals Corporation $13.6902/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 660180449 CMS
GENZYME CORPORATION $124.8602/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693946461 CMS
Supernus Pharmaceuticals, Inc. $17.6202/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 702370301 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $137,842.56 216
PY2020 $88,328.13 104
PY2021 $28,734.06 94
PY2022 $48,128.23 115
PY2023 $34,694.98 110
PY2024 $28,371.07 109
PY2025 $10,441.15 54

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $102,594.64 24
PY2025 Principal investigator $4,308,530.70 399
PY2024 Recipient $683,083.05 117
PY2024 Principal investigator $3,539,953.58 333
PY2023 Recipient $604,756.50 136
PY2023 Principal investigator $4,147,950.42 203
PY2022 Recipient $182,446.41 68
PY2022 Principal investigator $4,281,973.08 159
PY2021 Recipient $307,167.78 80
PY2021 Principal investigator $2,352,572.30 85
PY2020 Recipient $121,997.32 42
PY2020 Principal investigator $1,469,195.04 43
PY2019 Recipient $91,632.25 46
PY2019 Principal investigator $1,085,250.60 84

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

423 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 GENZYME CORPORATION $455.00 12/22/2025 Non-covered Recipient Entity
Sibyl Wray Md Neurology Pc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226152339
Principal investigator 1 GENZYME CORPORATION $96.00 12/22/2025 Non-covered Recipient Entity
Sibyl Wray Md Neurology Pc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226152345
Principal investigator 1 Genentech, Inc. $10,964.00 12/22/2025 Non-covered Recipient Entity
SIBYL WRAY MD NEUROLOGY PC
A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS) (PORTAMENTO) No dispute reported 06/30/2026 1211655020
Principal investigator 1 F. Hoffmann-La Roche AG $8,473.00 12/19/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654882
Principal investigator 1 Genentech, Inc. $3,374.00 12/19/2025 Non-covered Recipient Entity
SIBYL WRAY MD NEUROLOGY PC
Evaluation of Fenebrutinib in RMS patients II No dispute reported 06/30/2026 1211655409
Principal investigator 1 Genentech, Inc. $1,954.00 12/17/2025 Non-covered Recipient Entity
SIBYL WRAY MD NEUROLOGY PC
OCARINA 3 No dispute reported 06/30/2026 1211655023
Principal investigator 1 Genentech, Inc. $27,033.00 12/16/2025 Non-covered Recipient Entity
SIBYL WRAY MD NEUROLOGY PC
A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS) (PORTAMENTO) No dispute reported 06/30/2026 1211655015
Principal investigator 1 Genentech, Inc. $8,918.00 12/16/2025 Non-covered Recipient Entity
SIBYL WRAY MD NEUROLOGY PC
Evaluation of Fenebrutinib in RMS patients II No dispute reported 06/30/2026 1211655399
Principal investigator 1 F. Hoffmann-La Roche AG $69.00 12/12/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654864
Principal investigator 1 F. Hoffmann-La Roche AG $69.00 12/12/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654869
Principal investigator 1 F. Hoffmann-La Roche AG $300.00 12/12/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654873
Principal investigator 1 F. Hoffmann-La Roche AG $125.00 12/12/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654877
Principal investigator 1 F. Hoffmann-La Roche AG $118.02 12/12/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654885
Principal investigator 1 F. Hoffmann-La Roche AG $500.00 12/12/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654890
Principal investigator 1 F. Hoffmann-La Roche AG $300.00 12/12/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654893
Principal investigator 1 F. Hoffmann-La Roche AG $78.00 12/12/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654896
Principal investigator 1 F. Hoffmann-La Roche AG $69.00 12/12/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654899
Principal investigator 1 F. Hoffmann-La Roche AG $118.02 12/12/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654903
Principal investigator 1 F. Hoffmann-La Roche AG $300.00 12/12/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654906
Principal investigator 1 F. Hoffmann-La Roche AG $500.00 12/12/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654910
Principal investigator 1 F. Hoffmann-La Roche AG $156.00 12/12/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654918
Principal investigator 1 F. Hoffmann-La Roche AG $69.00 12/12/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654925
Principal investigator 1 F. Hoffmann-La Roche AG $1,000.00 12/12/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654928
Principal investigator 1 F. Hoffmann-La Roche AG $69.00 12/12/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654932
Principal investigator 1 F. Hoffmann-La Roche AG $500.00 12/12/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654936
Principal investigator 1 Genentech, Inc. $1,719.00 12/12/2025 Non-covered Recipient Entity
SIBYL WRAY MD NEUROLOGY PC
OCARINA 3 No dispute reported 06/30/2026 1211655011
Principal investigator 1 TG Therapeutics, Inc. $167.00 12/11/2025 Non-covered Recipient Entity
Hope Neurology MS Center
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198071
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $950.00 12/10/2025 Non-covered Recipient Entity
Sibyl Wray Md Neourology Pc
A Phase 2, Randomized, Double-blind, Four-arm, Placebo-controlled, Multicenter Study Assessing the Efficacy, Safety and Tolerability of three doses of orally administered BMS-986368, a FAAH/MAGL Inhibitor, vs. placebo for the Treatment of Spasticity in Participants with Multiple Sclerosis. No dispute reported 06/30/2026 1235993695
Principal investigator 1 Genentech, Inc. $228.00 12/09/2025 Non-covered Recipient Entity
SIBYL WRAY MD NEUROLOGY PC
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211655269
Principal investigator 1 Genentech, Inc. $9,035.00 12/05/2025 Non-covered Recipient Entity
SIBYL WRAY MD NEUROLOGY PC
Evaluation of Fenebrutinib in RMS patients II No dispute reported 06/30/2026 1211655394
Principal investigator 1 Genentech, Inc. $8,848.00 12/04/2025 Non-covered Recipient Entity
SIBYL WRAY MD NEUROLOGY PC
Ocrelizumab RMS High Dose Study No dispute reported 06/30/2026 1211655275
Principal investigator 1 Genentech, Inc. $133.00 12/01/2025 Non-covered Recipient Entity
SIBYL WRAY MD NEUROLOGY PC
Evaluation of Fenebrutinib in RMS patients II No dispute reported 06/30/2026 1211655403
Principal investigator 1 TG Therapeutics, Inc. $21,688.15 12/01/2025 Non-covered Recipient Entity
Hope Neurology MS Center
TG1101-RMS303 An Open Label Extension Study of Ublituximab in Subjects with Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1226198091
Principal investigator 1 TG Therapeutics, Inc. $18,614.50 11/30/2025 Non-covered Recipient Entity
Hope Neurology MS Center
TG1101-RMS303 An Open Label Extension Study of Ublituximab in Subjects with Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1226198085
Principal investigator 1 Genentech, Inc. $1,285.00 11/25/2025 Non-covered Recipient Entity
SIBYL WRAY MD NEUROLOGY PC
OCARINA 3 No dispute reported 06/30/2026 1211655004
Principal investigator 1 GENZYME CORPORATION $3,069.00 11/24/2025 Non-covered Recipient Entity
Sibyl Wray Md Neurology Pc
Long-term Extension Safety and Efficacy Study of SAR442168 in Participants With Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1226152334
Principal investigator 1 Genentech, Inc. $15,995.00 11/20/2025 Non-covered Recipient Entity
SIBYL WRAY MD NEUROLOGY PC
A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS) (PORTAMENTO) No dispute reported 06/30/2026 1211655008
Principal investigator 1 Genentech, Inc. $1,390.00 11/20/2025 Non-covered Recipient Entity
SIBYL WRAY MD NEUROLOGY PC
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211655261
Principal investigator 1 Genentech, Inc. $5,032.00 11/20/2025 Non-covered Recipient Entity
SIBYL WRAY MD NEUROLOGY PC
Evaluation of Fenebrutinib in RMS patients II No dispute reported 06/30/2026 1211655386
Principal investigator 1 F. Hoffmann-La Roche AG $2,680.00 11/19/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654914
Principal investigator 1 F. Hoffmann-La Roche AG $242.00 11/19/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654922
Principal investigator 1 GENZYME CORPORATION $8,366.60 11/17/2025 Non-covered Recipient Entity
Sibyl Wray Md Neurology Pc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226152308
Principal investigator 1 GENZYME CORPORATION $11,842.30 11/17/2025 Non-covered Recipient Entity
Sibyl Wray Md Neurology Pc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226152314
Principal investigator 1 Genentech, Inc. $65.00 11/17/2025 Non-covered Recipient Entity
SIBYL WRAY MD NEUROLOGY PC
Evaluation of Fenebrutinib in RMS patients II No dispute reported 06/30/2026 1211655388
Principal investigator 1 TG Therapeutics, Inc. $2,401.74 11/12/2025 Non-covered Recipient Entity
Hope Neurology MS Center
TG1101-RMS303 An Open Label Extension Study of Ublituximab in Subjects with Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1226198061
Principal investigator 1 Genentech, Inc. $92.00 11/10/2025 Non-covered Recipient Entity
SIBYL WRAY MD NEUROLOGY PC
Ocrelizumab RMS High Dose Study No dispute reported 06/30/2026 1211655265
Recipient Novartis Pharmaceuticals Corporation $509.29 11/07/2025 Covered Recipient Physician Research Publication/ Writing Support No dispute reported 06/30/2026 1190291573
Principal investigator 1 Genentech, Inc. $210.00 11/05/2025 Non-covered Recipient Entity
SIBYL WRAY MD NEUROLOGY PC
OCARINA 3 No dispute reported 06/30/2026 1211654994
Principal investigator 1 TG Therapeutics, Inc. $9,189.45 11/01/2025 Non-covered Recipient Entity
Hope Neurology MS Center
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198063
Principal investigator 1 TG Therapeutics, Inc. $10,182.00 11/01/2025 Non-covered Recipient Entity
Hope Neurology MS Center
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198069
Principal investigator 1 TG Therapeutics, Inc. $3,099.30 11/01/2025 Non-covered Recipient Entity
Hope Neurology MS Center
TG1101-RMS303 An Open Label Extension Study of Ublituximab in Subjects with Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1226198083
Principal investigator 1 TG Therapeutics, Inc. $75.00 10/30/2025 Non-covered Recipient Entity
Hope Neurology MS Center
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198067
Principal investigator 1 TG Therapeutics, Inc. $5,303.50 10/30/2025 Non-covered Recipient Entity
Hope Neurology MS Center
TG1101-RMS303 An Open Label Extension Study of Ublituximab in Subjects with Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1226198089
Principal investigator 1 Genentech, Inc. $5,725.00 10/28/2025 Non-covered Recipient Entity
SIBYL WRAY MD NEUROLOGY PC
OCARINA 3 No dispute reported 06/30/2026 1211655001
Principal investigator 1 Genentech, Inc. $2,261.00 10/28/2025 Non-covered Recipient Entity
SIBYL WRAY MD NEUROLOGY PC
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211655243
Principal investigator 1 Genentech, Inc. $2,006.00 10/28/2025 Non-covered Recipient Entity
SIBYL WRAY MD NEUROLOGY PC
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211655254
Principal investigator 1 Genentech, Inc. $1,000.00 10/27/2025 Non-covered Recipient Entity
SIBYL WRAY MD NEUROLOGY PC
Ocrelizumab RMS High Dose Study No dispute reported 06/30/2026 1211655257
Principal investigator 1 Genentech, Inc. $223.00 10/23/2025 Non-covered Recipient Entity
SIBYL WRAY MD NEUROLOGY PC
Evaluation of Fenebrutinib in RMS patients II No dispute reported 06/30/2026 1211655370
Principal investigator 1 Genentech, Inc. $9,561.00 10/23/2025 Non-covered Recipient Entity
SIBYL WRAY MD NEUROLOGY PC
Evaluation of Fenebrutinib in RMS patients II No dispute reported 06/30/2026 1211655380
Principal investigator 1 F. Hoffmann-La Roche AG $242.00 10/22/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654793
Principal investigator 1 F. Hoffmann-La Roche AG $2,680.00 10/22/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654834
Principal investigator 1 F. Hoffmann-La Roche AG $693.00 10/22/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654847
Principal investigator 1 GENZYME CORPORATION $2,700.00 10/20/2025 Non-covered Recipient Entity
Sibyl Wray Md Neurology Pc
An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226152191
Principal investigator 1 GENZYME CORPORATION $175.48 10/20/2025 Non-covered Recipient Entity
Sibyl Wray Md Neurology Pc
An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226152198
Principal investigator 1 GENZYME CORPORATION $1,392.01 10/20/2025 Non-covered Recipient Entity
Sibyl Wray Md Neurology Pc
An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226152228
Principal investigator 1 GENZYME CORPORATION $336.70 10/20/2025 Non-covered Recipient Entity
Sibyl Wray Md Neurology Pc
An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226152233
Principal investigator 1 GENZYME CORPORATION $1,085.00 10/20/2025 Non-covered Recipient Entity
Sibyl Wray Md Neurology Pc
An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226152251
Principal investigator 1 Genentech, Inc. $126.00 10/20/2025 Non-covered Recipient Entity
SIBYL WRAY MD NEUROLOGY PC
Evaluation of Fenebrutinib in RMS patients II No dispute reported 06/30/2026 1211655383
Principal investigator 1 Genentech, Inc. $1,000.00 10/17/2025 Non-covered Recipient Entity
SIBYL WRAY MD NEUROLOGY PC
Evaluation of Fenebrutinib in RMS patients II No dispute reported 06/30/2026 1211655373
Principal investigator 1 Genentech, Inc. $2,516.00 10/15/2025 Non-covered Recipient Entity
SIBYL WRAY MD NEUROLOGY PC
Evaluation of Fenebrutinib in RMS patients II No dispute reported 06/30/2026 1211655376
Principal investigator 1 GENZYME CORPORATION $1,107.00 10/14/2025 Non-covered Recipient Entity
Sibyl Wray Md Neurology Pc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226152205
Principal investigator 1 GENZYME CORPORATION $682.89 10/14/2025 Non-covered Recipient Entity
Sibyl Wray Md Neurology Pc
An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226152211
Principal investigator 1 GENZYME CORPORATION $656.80 10/14/2025 Non-covered Recipient Entity
Sibyl Wray Md Neurology Pc
An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226152215
Principal investigator 1 GENZYME CORPORATION $136.80 10/14/2025 Non-covered Recipient Entity
Sibyl Wray Md Neurology Pc
An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226152219
Principal investigator 1 GENZYME CORPORATION $115.00 10/14/2025 Non-covered Recipient Entity
Sibyl Wray Md Neurology Pc
An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226152224
Principal investigator 1 GENZYME CORPORATION $1,755.00 10/14/2025 Non-covered Recipient Entity
Sibyl Wray Md Neurology Pc
An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226152238
Principal investigator 1 GENZYME CORPORATION $166.24 10/14/2025 Non-covered Recipient Entity
Sibyl Wray Md Neurology Pc
An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226152243
Principal investigator 1 Genentech, Inc. $1,240.00 10/09/2025 Non-covered Recipient Entity
SIBYL WRAY MD NEUROLOGY PC
OCARINA 3 No dispute reported 06/30/2026 1211654998
Principal investigator 1 Genentech, Inc. $1,000.00 10/09/2025 Non-covered Recipient Entity
SIBYL WRAY MD NEUROLOGY PC
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211655250
Principal investigator 1 TG Therapeutics, Inc. $4,298.88 10/08/2025 Non-covered Recipient Entity
Hope Neurology MS Center
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198065
Principal investigator 1 TG Therapeutics, Inc. $4,137.24 10/08/2025 Non-covered Recipient Entity
Hope Neurology MS Center
TG1101-RMS303 An Open Label Extension Study of Ublituximab in Subjects with Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1226198087
Principal investigator 1 Novartis Pharmaceuticals Corporation $878.52 10/07/2025 Non-covered Recipient Entity
SIBYL WRAY MD NEUROLOGY PC
A Randomized, Open-label, Parallel-group, Non-inferiority Study Comparing Efficacy, Safety, and Tolerability of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis, Followed by Open-label Treatment With R No dispute reported 06/30/2026 1190300089
Principal investigator 1 F. Hoffmann-La Roche AG $84.84 10/02/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654797
Principal investigator 1 F. Hoffmann-La Roche AG $500.00 10/02/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654801
Principal investigator 1 F. Hoffmann-La Roche AG $1,000.00 10/02/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654806
Principal investigator 1 F. Hoffmann-La Roche AG $69.00 10/02/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654812
Principal investigator 1 F. Hoffmann-La Roche AG $156.00 10/02/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654815
Principal investigator 1 F. Hoffmann-La Roche AG $125.00 10/02/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654819
Principal investigator 1 F. Hoffmann-La Roche AG $69.00 10/02/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654824
Principal investigator 1 F. Hoffmann-La Roche AG $84.84 10/02/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654826
Principal investigator 1 F. Hoffmann-La Roche AG $69.00 10/02/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654830
Principal investigator 1 F. Hoffmann-La Roche AG $69.00 10/02/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654837
Principal investigator 1 F. Hoffmann-La Roche AG $69.00 10/02/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654842
Principal investigator 1 F. Hoffmann-La Roche AG $125.00 10/02/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654850
Principal investigator 1 F. Hoffmann-La Roche AG $300.00 10/02/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654854
Principal investigator 1 F. Hoffmann-La Roche AG $32.40 10/02/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654859
Principal investigator 1 TG Therapeutics, Inc. $2,644.65 09/30/2025 Non-covered Recipient Entity
Hope Neurology MS Center
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198003
Principal investigator 1 TG Therapeutics, Inc. $6,236.00 09/30/2025 Non-covered Recipient Entity
Hope Neurology MS Center
TG1101-RMS303 An Open Label Extension Study of Ublituximab in Subjects with Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1226198041
Principal investigator 1 GENZYME CORPORATION $5,682.90 09/29/2025 Non-covered Recipient Entity
Sibyl Wray Md Neurology Pc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226152171
Principal investigator 1 Genentech, Inc. $2,282.00 09/29/2025 Non-covered Recipient Entity
SIBYL WRAY MD NEUROLOGY PC
OCARINA 3 No dispute reported 06/30/2026 1211654981
Principal investigator 1 Celgene Corporation $25,937.00 09/26/2025 Non-covered Recipient Entity
Hope Neurology, PLLC
A Phase 2, Randomized, Double-blind, Four-arm, Placebo-controlled, Multicenter Study Assessing the Efficacy, Safety and Tolerability of three doses of orally administered BMS-986368, a FAAH/MAGL Inhibitor, vs. placebo for the Treatment of Spasticity in Participants with Multiple Sclerosis. No dispute reported 06/30/2026 1222306233
Principal investigator 1 Genentech, Inc. $136.00 09/25/2025 Non-covered Recipient Entity
SIBYL WRAY MD NEUROLOGY PC
Evaluation of Fenebrutinib in RMS patients II No dispute reported 06/30/2026 1211655362
Principal investigator 1 Genentech, Inc. $185.00 09/25/2025 Non-covered Recipient Entity
SIBYL WRAY MD NEUROLOGY PC
Evaluation of Fenebrutinib in RMS patients II No dispute reported 06/30/2026 1211655366
Principal investigator 1 TG Therapeutics, Inc. $5,604.06 09/25/2025 Non-covered Recipient Entity
Hope Neurology MS Center
TG1101-RMS303 An Open Label Extension Study of Ublituximab in Subjects with Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1226198059
Principal investigator 1 Genentech, Inc. $56.00 09/24/2025 Non-covered Recipient Entity
SIBYL WRAY MD NEUROLOGY PC
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211655217
Principal investigator 1 Genentech, Inc. $161.00 09/24/2025 Non-covered Recipient Entity
SIBYL WRAY MD NEUROLOGY PC
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211655227
Recipient Novartis Pharma AG $76.67 09/24/2025 Covered Recipient Physician CLOU064C12301, CLOU064C12302 No dispute reported 06/30/2026 1248109023
Principal investigator 1 Roche Products Limited $338.00 09/24/2025 Non-covered Recipient Entity
SIBYL WRAY MD NEUROLOGY PC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211655104
Principal investigator 1 Roche Products Limited $338.00 09/24/2025 Non-covered Recipient Entity
SIBYL WRAY MD NEUROLOGY PC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211655107
Principal investigator 1 Roche Products Limited $338.00 09/24/2025 Non-covered Recipient Entity
SIBYL WRAY MD NEUROLOGY PC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211655111
Principal investigator 1 Roche Products Limited $338.00 09/24/2025 Non-covered Recipient Entity
SIBYL WRAY MD NEUROLOGY PC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211655115
Principal investigator 1 Roche Products Limited $338.00 09/24/2025 Non-covered Recipient Entity
SIBYL WRAY MD NEUROLOGY PC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211655119
Principal investigator 1 Roche Products Limited $338.00 09/24/2025 Non-covered Recipient Entity
SIBYL WRAY MD NEUROLOGY PC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211655123
Principal investigator 1 Roche Products Limited $338.00 09/24/2025 Non-covered Recipient Entity
SIBYL WRAY MD NEUROLOGY PC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211655127
Principal investigator 1 Roche Products Limited $33.80 09/24/2025 Non-covered Recipient Entity
SIBYL WRAY MD NEUROLOGY PC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211655138
Principal investigator 1 Roche Products Limited $338.00 09/24/2025 Non-covered Recipient Entity
SIBYL WRAY MD NEUROLOGY PC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211655142
Principal investigator 1 Roche Products Limited $338.00 09/24/2025 Non-covered Recipient Entity
SIBYL WRAY MD NEUROLOGY PC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211655146
Principal investigator 1 F. Hoffmann-La Roche AG $693.00 09/22/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654700
Principal investigator 1 Genentech, Inc. $9,007.00 09/22/2025 Non-covered Recipient Entity
SIBYL WRAY MD NEUROLOGY PC
Ocrelizumab RMS High Dose Study No dispute reported 06/30/2026 1211655234
Principal investigator 1 Genentech, Inc. $8,116.00 09/18/2025 Non-covered Recipient Entity
SIBYL WRAY MD NEUROLOGY PC
Evaluation of Fenebrutinib in RMS patients II No dispute reported 06/30/2026 1211655344
Principal investigator 1 TG Therapeutics, Inc. $285.00 09/16/2025 Non-covered Recipient Entity
Hope Neurology MS Center
TG1101-RMS303 An Open Label Extension Study of Ublituximab in Subjects with Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1226198053
Principal investigator 1 F. Hoffmann-La Roche AG $69.00 09/15/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654718
Principal investigator 1 F. Hoffmann-La Roche AG $69.00 09/15/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654720
Principal investigator 1 F. Hoffmann-La Roche AG $125.00 09/15/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654724
Principal investigator 1 F. Hoffmann-La Roche AG $693.00 09/15/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654729
Principal investigator 1 F. Hoffmann-La Roche AG $500.00 09/15/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654734
Principal investigator 1 F. Hoffmann-La Roche AG $31.92 09/15/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654742
Principal investigator 1 F. Hoffmann-La Roche AG $242.00 09/15/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654758
Principal investigator 1 F. Hoffmann-La Roche AG $69.00 09/15/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654771
Principal investigator 1 F. Hoffmann-La Roche AG $300.00 09/15/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654785
Principal investigator 1 F. Hoffmann-La Roche AG $39.00 09/15/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654790
Principal investigator 1 TG Therapeutics, Inc. $6,548.50 09/10/2025 Non-covered Recipient Entity
Hope Neurology MS Center
TG1101-RMS303 An Open Label Extension Study of Ublituximab in Subjects with Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1226198051
Principal investigator 1 GENZYME CORPORATION $670.00 09/08/2025 Non-covered Recipient Entity
Sibyl Wray Md Neurology Pc
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226152158
Recipient TG Therapeutics, Inc. $807.35 09/08/2025 Covered Recipient Physician RMS302 No dispute reported 06/30/2026 1226200850
Principal investigator 1 Genentech, Inc. $2,800.00 09/03/2025 Non-covered Recipient Entity
SIBYL WRAY MD NEUROLOGY PC
Evaluation of Fenebrutinib in RMS patients II No dispute reported 06/30/2026 1211655348
Principal investigator 1 TG Therapeutics, Inc. $1,781.00 08/31/2025 Non-covered Recipient Entity
Hope Neurology MS Center
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198001
Principal investigator 1 TG Therapeutics, Inc. $9,335.30 08/31/2025 Non-covered Recipient Entity
Hope Neurology MS Center
TG1101-RMS303 An Open Label Extension Study of Ublituximab in Subjects with Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1226198039
Principal investigator 1 Genentech, Inc. $1,113.00 08/27/2025 Non-covered Recipient Entity
SIBYL WRAY MD NEUROLOGY PC
OCARINA 3 No dispute reported 06/30/2026 1211654977
Principal investigator 1 GENZYME CORPORATION $32.00 08/25/2025 Non-covered Recipient Entity
Sibyl Wray Md Neurology Pc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226152128
Principal investigator 1 GENZYME CORPORATION $202.00 08/25/2025 Non-covered Recipient Entity
Sibyl Wray Md Neurology Pc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226152140
Principal investigator 1 Genentech, Inc. $56.00 08/22/2025 Non-covered Recipient Entity
SIBYL WRAY MD NEUROLOGY PC
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211655221
Principal investigator 1 Genentech, Inc. $8,886.00 08/20/2025 Non-covered Recipient Entity
SIBYL WRAY MD NEUROLOGY PC
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211655224
Principal investigator 1 GENZYME CORPORATION $32.00 08/18/2025 Non-covered Recipient Entity
Sibyl Wray Md Neurology Pc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226152122
Principal investigator 1 Genentech, Inc. $68.00 08/18/2025 Non-covered Recipient Entity
SIBYL WRAY MD NEUROLOGY PC
Evaluation of Fenebrutinib in RMS patients II No dispute reported 06/30/2026 1211655358
Principal investigator 1 Genentech, Inc. $5,890.00 08/15/2025 Non-covered Recipient Entity
SIBYL WRAY MD NEUROLOGY PC
Ocrelizumab RMS High Dose Study No dispute reported 06/30/2026 1211655239
Principal investigator 1 Genentech, Inc. $2,370.00 08/13/2025 Non-covered Recipient Entity
SIBYL WRAY MD NEUROLOGY PC
OCARINA 3 No dispute reported 06/30/2026 1211654990
Principal investigator 1 TG Therapeutics, Inc. $849.78 08/13/2025 Non-covered Recipient Entity
Hope Neurology MS Center
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198015
Principal investigator 1 TG Therapeutics, Inc. $4,924.50 08/12/2025 Non-covered Recipient Entity
Hope Neurology MS Center
TG1101-RMS303 An Open Label Extension Study of Ublituximab in Subjects with Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1226198049
Principal investigator 1 GENZYME CORPORATION $80,214.00 08/11/2025 Non-covered Recipient Entity
Sibyl Wray Md Neurology Pc
An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226152113
Principal investigator 1 Genentech, Inc. $1,817.00 08/11/2025 Non-covered Recipient Entity
SIBYL WRAY MD NEUROLOGY PC
Evaluation of Fenebrutinib in RMS patients II No dispute reported 06/30/2026 1211655354
Principal investigator 1 Genentech, Inc. $850.00 08/07/2025 Non-covered Recipient Entity
SIBYL WRAY MD NEUROLOGY PC
OCARINA 3 No dispute reported 06/30/2026 1211654987
Principal investigator 1 TG Therapeutics, Inc. $1,601.16 08/07/2025 Non-covered Recipient Entity
Hope Neurology MS Center
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198057
Principal investigator 1 GENZYME CORPORATION $6,044.30 08/04/2025 Non-covered Recipient Entity
Sibyl Wray Md Neurology Pc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226152051
Principal investigator 1 GENZYME CORPORATION $12,088.60 08/04/2025 Non-covered Recipient Entity
Sibyl Wray Md Neurology Pc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226152057
Principal investigator 1 TG Therapeutics, Inc. $12,664.00 08/01/2025 Non-covered Recipient Entity
Hope Neurology MS Center
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198013
Principal investigator 1 TG Therapeutics, Inc. $8,629.25 07/31/2025 Non-covered Recipient Entity
Hope Neurology MS Center
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226197999
Principal investigator 1 TG Therapeutics, Inc. $12,415.90 07/31/2025 Non-covered Recipient Entity
Hope Neurology MS Center
TG1101-RMS303 An Open Label Extension Study of Ublituximab in Subjects with Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1226198037
Principal investigator 1 TG Therapeutics, Inc. $574.50 07/29/2025 Non-covered Recipient Entity
Hope Neurology MS Center
TG1101-RMS303 An Open Label Extension Study of Ublituximab in Subjects with Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1226198047
Principal investigator 1 GENZYME CORPORATION $500.00 07/28/2025 Non-covered Recipient Entity
Sibyl Wray Md Neurology Pc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226152101
Principal investigator 1 GENZYME CORPORATION $939.00 07/28/2025 Non-covered Recipient Entity
Sibyl Wray Md Neurology Pc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226152716
Principal investigator 1 Roche Products Limited $750.00 07/28/2025 Non-covered Recipient Entity
SIBYL WRAY MD NEUROLOGY PC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211655134
Principal investigator 1 TG Therapeutics, Inc. $150.00 07/28/2025 Non-covered Recipient Entity
Hope Neurology MS Center
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198011
Principal investigator 1 F. Hoffmann-La Roche AG $125.00 07/23/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654703
Principal investigator 1 F. Hoffmann-La Roche AG $693.00 07/23/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654706
Principal investigator 1 F. Hoffmann-La Roche AG $31.92 07/23/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654713
Principal investigator 1 F. Hoffmann-La Roche AG $242.00 07/23/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654731
Principal investigator 1 F. Hoffmann-La Roche AG $69.00 07/23/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654738
Principal investigator 1 F. Hoffmann-La Roche AG $2,680.00 07/23/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654761
Principal investigator 1 F. Hoffmann-La Roche AG $69.00 07/23/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654781
Principal investigator 1 Genentech, Inc. $5,757.00 07/21/2025 Non-covered Recipient Entity
SIBYL WRAY MD NEUROLOGY PC
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211655210
Principal investigator 1 Genentech, Inc. $2,800.00 07/21/2025 Non-covered Recipient Entity
SIBYL WRAY MD NEUROLOGY PC
Evaluation of Fenebrutinib in RMS patients II No dispute reported 06/30/2026 1211655336
Principal investigator 1 TG Therapeutics, Inc. $574.50 07/21/2025 Non-covered Recipient Entity
Hope Neurology MS Center
TG1101-RMS303 An Open Label Extension Study of Ublituximab in Subjects with Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1226198045
Principal investigator 1 TG Therapeutics, Inc. $866.78 07/20/2025 Non-covered Recipient Entity
Hope Neurology MS Center
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198009
Principal investigator 1 TG Therapeutics, Inc. $225.00 07/16/2025 Non-covered Recipient Entity
Hope Neurology MS Center
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198007
Principal investigator 1 Genentech, Inc. $75.00 07/10/2025 Non-covered Recipient Entity
SIBYL WRAY MD NEUROLOGY PC
OCARINA 3 No dispute reported 06/30/2026 1211654974
Principal investigator 1 Genentech, Inc. $1,452.00 07/10/2025 Non-covered Recipient Entity
SIBYL WRAY MD NEUROLOGY PC
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211655214
Principal investigator 1 Genentech, Inc. $9,363.00 07/09/2025 Non-covered Recipient Entity
SIBYL WRAY MD NEUROLOGY PC
Evaluation of Fenebrutinib in RMS patients II No dispute reported 06/30/2026 1211655340
Principal investigator 1 TG Therapeutics, Inc. $4,002.90 07/07/2025 Non-covered Recipient Entity
Hope Neurology MS Center
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198055
Principal investigator 1 F. Hoffmann-La Roche AG $438.00 07/02/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654709
Principal investigator 1 F. Hoffmann-La Roche AG $44.00 07/02/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654745
Principal investigator 1 F. Hoffmann-La Roche AG $31.92 07/02/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654749
Principal investigator 1 F. Hoffmann-La Roche AG $24.00 07/02/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654754
Principal investigator 1 F. Hoffmann-La Roche AG $291.00 07/02/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654767
Principal investigator 1 F. Hoffmann-La Roche AG $125.00 07/02/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654776
Principal investigator 1 GENZYME CORPORATION $5,682.90 07/02/2025 Non-covered Recipient Entity
Sibyl Wray Md Neurology Pc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226152690
Principal investigator 1 Genentech, Inc. $9,135.00 07/02/2025 Non-covered Recipient Entity
SIBYL WRAY MD NEUROLOGY PC
Ocrelizumab RMS High Dose Study No dispute reported 06/30/2026 1211655158
Principal investigator 1 Genentech, Inc. $136.00 07/02/2025 Non-covered Recipient Entity
SIBYL WRAY MD NEUROLOGY PC
Evaluation of Fenebrutinib in RMS patients II No dispute reported 06/30/2026 1211655296
Principal investigator 1 TG Therapeutics, Inc. $2,778.94 07/02/2025 Non-covered Recipient Entity
Hope Neurology MS Center
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198005
Principal investigator 1 TG Therapeutics, Inc. $1,635.44 07/02/2025 Non-covered Recipient Entity
Hope Neurology MS Center
TG1101-RMS303 An Open Label Extension Study of Ublituximab in Subjects with Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1226198043
Principal investigator 1 Genentech, Inc. $8,725.00 07/01/2025 Non-covered Recipient Entity
SIBYL WRAY MD NEUROLOGY PC
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211655166
Principal investigator 1 TG Therapeutics, Inc. $1,742.34 06/26/2025 Non-covered Recipient Entity
Hope Neurology MS Center
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226197941
Principal investigator 1 TG Therapeutics, Inc. $900.00 06/26/2025 Non-covered Recipient Entity
Hope Neurology MS Center
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226197943
Principal investigator 1 Genentech, Inc. $441.00 06/25/2025 Non-covered Recipient Entity
SIBYL WRAY MD NEUROLOGY PC
OCARINA 3 No dispute reported 06/30/2026 1211654941
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $1,652.84 06/24/2025 Non-covered Recipient Entity
Hope Neurology, PLLC
A Phase 2, Randomized, Double-blind, Four-arm, Placebo-controlled, Multicenter Study Assessing the Efficacy, Safety and Tolerability of three doses of orally administered BMS-986368, a FAAH/MAGL Inhibitor, vs. placebo for the Treatment of Spasticity in Participants with Multiple Sclerosis. No dispute reported 06/30/2026 1235996845
Principal investigator 1 Genentech, Inc. $5,890.00 06/24/2025 Non-covered Recipient Entity
SIBYL WRAY MD NEUROLOGY PC
Ocrelizumab RMS High Dose Study No dispute reported 06/30/2026 1211655173
Principal investigator 1 Genentech, Inc. $5,032.00 06/24/2025 Non-covered Recipient Entity
SIBYL WRAY MD NEUROLOGY PC
Evaluation of Fenebrutinib in RMS patients II No dispute reported 06/30/2026 1211655292
Principal investigator 1 Roche Products Limited $338.00 06/24/2025 Non-covered Recipient Entity
SIBYL WRAY MD NEUROLOGY PC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211655078
Principal investigator 1 Roche Products Limited $338.00 06/24/2025 Non-covered Recipient Entity
SIBYL WRAY MD NEUROLOGY PC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211655082
Principal investigator 1 Roche Products Limited $338.00 06/24/2025 Non-covered Recipient Entity
SIBYL WRAY MD NEUROLOGY PC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211655085
Principal investigator 1 Roche Products Limited $338.00 06/24/2025 Non-covered Recipient Entity
SIBYL WRAY MD NEUROLOGY PC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211655089
Principal investigator 1 Roche Products Limited $338.00 06/24/2025 Non-covered Recipient Entity
SIBYL WRAY MD NEUROLOGY PC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211655093
Principal investigator 1 Roche Products Limited $338.00 06/24/2025 Non-covered Recipient Entity
SIBYL WRAY MD NEUROLOGY PC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211655099
Principal investigator 1 F. Hoffmann-La Roche AG $693.00 06/20/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654528
Principal investigator 1 F. Hoffmann-La Roche AG $242.00 06/20/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654550
Principal investigator 1 F. Hoffmann-La Roche AG $1,000.00 06/20/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654569
Principal investigator 1 F. Hoffmann-La Roche AG $69.00 06/20/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654595
Principal investigator 1 F. Hoffmann-La Roche AG $125.00 06/20/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654603
Principal investigator 1 F. Hoffmann-La Roche AG $69.00 06/20/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654665
Principal investigator 1 F. Hoffmann-La Roche AG $2,680.00 06/20/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654671
Principal investigator 1 F. Hoffmann-La Roche AG $300.00 06/20/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654675
Principal investigator 1 F. Hoffmann-La Roche AG $69.00 06/20/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654684
Principal investigator 1 F. Hoffmann-La Roche AG $693.00 06/20/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654688
Principal investigator 1 F. Hoffmann-La Roche AG $500.00 06/20/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654691
Principal investigator 1 Genentech, Inc. $1,508.00 06/18/2025 Non-covered Recipient Entity
SIBYL WRAY MD NEUROLOGY PC
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211655177
Principal investigator 1 TG Therapeutics, Inc. $600.00 06/18/2025 Non-covered Recipient Entity
Hope Neurology MS Center
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226197939
Principal investigator 1 GENZYME CORPORATION $3,450.00 06/16/2025 Non-covered Recipient Entity
Sibyl Wray Md Neurology Pc
A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226152637
Principal investigator 1 Genentech, Inc. $133.00 06/16/2025 Non-covered Recipient Entity
SIBYL WRAY MD NEUROLOGY PC
Evaluation of Fenebrutinib in RMS patients II No dispute reported 06/30/2026 1211655281
Principal investigator 1 Genentech, Inc. $4,050.00 06/12/2025 Non-covered Recipient Entity
SIBYL WRAY MD NEUROLOGY PC
Ocrelizumab RMS High Dose Study No dispute reported 06/30/2026 1211655149
Principal investigator 1 Novartis Pharmaceuticals Corporation $7,423.00 06/12/2025 Non-covered Recipient Entity
SIBYL WRAY MD NEUROLOGY PC
A Randomized, Open-label, Parallel-group, Non-inferiority Study Comparing Efficacy, Safety, and Tolerability of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis, Followed by Open-label Treatment With R No dispute reported 06/30/2026 1190300091
Principal investigator 1 Genentech, Inc. $56.00 06/11/2025 Non-covered Recipient Entity
SIBYL WRAY MD NEUROLOGY PC
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211655154
Principal investigator 1 TG Therapeutics, Inc. $25.00 06/10/2025 Non-covered Recipient Entity
Hope Neurology MS Center
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226197937
Principal investigator 1 TG Therapeutics, Inc. $1,032.67 06/09/2025 Non-covered Recipient Entity
Hope Neurology MS Center
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226197935
Principal investigator 1 Genentech, Inc. $10,591.00 06/06/2025 Non-covered Recipient Entity
SIBYL WRAY MD NEUROLOGY PC
OCARINA 3 No dispute reported 06/30/2026 1211654948
Principal investigator 1 Genentech, Inc. $150.00 06/05/2025 Non-covered Recipient Entity
SIBYL WRAY MD NEUROLOGY PC
OCARINA 3 No dispute reported 06/30/2026 1211654944
Principal investigator 1 TG Therapeutics, Inc. $7,315.00 06/04/2025 Non-covered Recipient Entity
Hope Neurology MS Center
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226197931
Principal investigator 1 TG Therapeutics, Inc. $9,119.82 06/04/2025 Non-covered Recipient Entity
Hope Neurology MS Center
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226197933
Principal investigator 1 Genentech, Inc. $17,030.00 06/03/2025 Non-covered Recipient Entity
SIBYL WRAY MD NEUROLOGY PC
Ocrelizumab RMS High Dose Study No dispute reported 06/30/2026 1211655170
Recipient Novartis Pharmaceuticals Corporation $1,356.78 06/03/2025 Covered Recipient Physician Research Publication/Writing Support No dispute reported 06/30/2026 1190292769
Principal investigator 1 Genentech, Inc. $56.00 06/02/2025 Non-covered Recipient Entity
SIBYL WRAY MD NEUROLOGY PC
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211655162
Principal investigator 1 TG Therapeutics, Inc. $7,129.00 06/01/2025 Non-covered Recipient Entity
Hope Neurology MS Center
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226197929
Principal investigator 1 TG Therapeutics, Inc. $14,147.00 06/01/2025 Non-covered Recipient Entity
Hope Neurology MS Center
TG1101-RMS303 An Open Label Extension Study of Ublituximab in Subjects with Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1226197983
Principal investigator 1 TG Therapeutics, Inc. $2,401.74 05/29/2025 Non-covered Recipient Entity
Hope Neurology MS Center
TG1101-RMS303 An Open Label Extension Study of Ublituximab in Subjects with Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1226197997
Principal investigator 1 Genentech, Inc. $790.00 05/28/2025 Non-covered Recipient Entity
SIBYL WRAY MD NEUROLOGY PC
OCARINA 3 No dispute reported 06/30/2026 1211654951
Principal investigator 1 F. Hoffmann-La Roche AG $45.47 05/27/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654523
Principal investigator 1 F. Hoffmann-La Roche AG $125.00 05/27/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654532
Principal investigator 1 F. Hoffmann-La Roche AG $46.70 05/27/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654553
Principal investigator 1 F. Hoffmann-La Roche AG $1,000.00 05/27/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654558
Principal investigator 1 F. Hoffmann-La Roche AG $69.00 05/27/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654562
Principal investigator 1 F. Hoffmann-La Roche AG $69.00 05/27/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654564
Principal investigator 1 F. Hoffmann-La Roche AG $39.00 05/27/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654577
Principal investigator 1 F. Hoffmann-La Roche AG $1,000.00 05/27/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654591
Principal investigator 1 F. Hoffmann-La Roche AG $500.00 05/27/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654599
Principal investigator 1 F. Hoffmann-La Roche AG $156.00 05/27/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654607
Principal investigator 1 F. Hoffmann-La Roche AG $69.00 05/27/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654625
Principal investigator 1 F. Hoffmann-La Roche AG $8,473.00 05/27/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654627
Principal investigator 1 F. Hoffmann-La Roche AG $156.00 05/27/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654636
Principal investigator 1 F. Hoffmann-La Roche AG $69.00 05/27/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654639
Principal investigator 1 F. Hoffmann-La Roche AG $300.00 05/27/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654656
Principal investigator 1 F. Hoffmann-La Roche AG $693.00 05/27/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654662
Principal investigator 1 F. Hoffmann-La Roche AG $300.00 05/27/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654668
Principal investigator 1 F. Hoffmann-La Roche AG $500.00 05/27/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654696
Principal investigator 1 Genentech, Inc. $65.00 05/27/2025 Non-covered Recipient Entity
SIBYL WRAY MD NEUROLOGY PC
Evaluation of Fenebrutinib in RMS patients II No dispute reported 06/30/2026 1211655286
Principal investigator 1 Genentech, Inc. $68.00 05/20/2025 Non-covered Recipient Entity
SIBYL WRAY MD NEUROLOGY PC
Evaluation of Fenebrutinib in RMS patients II No dispute reported 06/30/2026 1211655300
Principal investigator 1 GENZYME CORPORATION $17,409.30 05/19/2025 Non-covered Recipient Entity
Sibyl Wray Md Neurology Pc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226152649
Principal investigator 1 GENZYME CORPORATION $607.00 05/19/2025 Non-covered Recipient Entity
Sibyl Wray Md Neurology Pc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226152657
Principal investigator 1 GENZYME CORPORATION $32.00 05/19/2025 Non-covered Recipient Entity
Sibyl Wray Md Neurology Pc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226152664
Principal investigator 1 GENZYME CORPORATION $5,175.00 05/19/2025 Non-covered Recipient Entity
Sibyl Wray Md Neurology Pc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226152669
Principal investigator 1 Genentech, Inc. $1,145.00 05/14/2025 Non-covered Recipient Entity
SIBYL WRAY MD NEUROLOGY PC
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211655187
Principal investigator 1 Genentech, Inc. $152,571.00 05/13/2025 Non-covered Recipient Entity
SIBYL WRAY MD NEUROLOGY PC
Ocrelizumab RMS High Dose Study No dispute reported 06/30/2026 1211655191
Principal investigator 1 Genentech, Inc. $2,516.00 05/13/2025 Non-covered Recipient Entity
SIBYL WRAY MD NEUROLOGY PC
Evaluation of Fenebrutinib in RMS patients II No dispute reported 06/30/2026 1211655312
Principal investigator 1 TG Therapeutics, Inc. $148.68 05/13/2025 Non-covered Recipient Entity
Hope Neurology MS Center
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226197927
Principal investigator 1 Genentech, Inc. $1,807.00 05/09/2025 Non-covered Recipient Entity
SIBYL WRAY MD NEUROLOGY PC
OCARINA 3 No dispute reported 06/30/2026 1211654959
Principal investigator 1 Genentech, Inc. $29,423.00 05/09/2025 Non-covered Recipient Entity
SIBYL WRAY MD NEUROLOGY PC
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211655202
Principal investigator 1 TG Therapeutics, Inc. $574.50 05/07/2025 Non-covered Recipient Entity
Hope Neurology MS Center
TG1101-RMS303 An Open Label Extension Study of Ublituximab in Subjects with Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1226197981
Principal investigator 1 GENZYME CORPORATION $92.01 05/05/2025 Non-covered Recipient Entity
Sibyl Wray Md Neurology Pc
An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226152554
Principal investigator 1 GENZYME CORPORATION $274.69 05/05/2025 Non-covered Recipient Entity
Sibyl Wray Md Neurology Pc
An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226152560
Principal investigator 1 GENZYME CORPORATION $170.44 05/05/2025 Non-covered Recipient Entity
Sibyl Wray Md Neurology Pc
An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226152566
Principal investigator 1 GENZYME CORPORATION $352.53 05/05/2025 Non-covered Recipient Entity
Sibyl Wray Md Neurology Pc
An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226152570
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $3,753.56 04/30/2025 Non-covered Recipient Entity
Hope Neurology, PLLC
A Phase 2, Randomized, Double-blind, Four-arm, Placebo-controlled, Multicenter Study Assessing the Efficacy, Safety and Tolerability of three doses of orally administered BMS-986368, a FAAH/MAGL Inhibitor, vs. placebo for the Treatment of Spasticity in Participants with Multiple Sclerosis. No dispute reported 06/30/2026 1235996847
Principal investigator 1 Genentech, Inc. $36,894.00 04/29/2025 Non-covered Recipient Entity
SIBYL WRAY MD NEUROLOGY PC
OCARINA 3 No dispute reported 06/30/2026 1211654966
Principal investigator 1 Genentech, Inc. $780.00 04/29/2025 Non-covered Recipient Entity
SIBYL WRAY MD NEUROLOGY PC
Evaluation of Fenebrutinib in RMS patients II No dispute reported 06/30/2026 1211655303
Principal investigator 1 GENZYME CORPORATION $5,339.00 04/28/2025 Non-covered Recipient Entity
Sibyl Wray Md Neurology Pc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226152544
Principal investigator 1 GENZYME CORPORATION $1,020.00 04/28/2025 Non-covered Recipient Entity
Sibyl Wray Md Neurology Pc
An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226152575
Principal investigator 1 GENZYME CORPORATION $5,600.00 04/28/2025 Non-covered Recipient Entity
Sibyl Wray Md Neurology Pc
An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226152584
Principal investigator 1 GENZYME CORPORATION $1,275.00 04/28/2025 Non-covered Recipient Entity
Sibyl Wray Md Neurology Pc
An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226152588
Principal investigator 1 Genentech, Inc. $2,516.00 04/28/2025 Non-covered Recipient Entity
SIBYL WRAY MD NEUROLOGY PC
Evaluation of Fenebrutinib in RMS patients II No dispute reported 06/30/2026 1211655315
Principal investigator 1 F. Hoffmann-La Roche AG $125.00 04/25/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654538
Principal investigator 1 F. Hoffmann-La Roche AG $500.00 04/25/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654544
Principal investigator 1 F. Hoffmann-La Roche AG $125.00 04/25/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654556
Principal investigator 1 F. Hoffmann-La Roche AG $500.00 04/25/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654574
Principal investigator 1 F. Hoffmann-La Roche AG $69.00 04/25/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654581
Principal investigator 1 F. Hoffmann-La Roche AG $69.00 04/25/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654586
Principal investigator 1 F. Hoffmann-La Roche AG $693.00 04/25/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654612
Principal investigator 1 F. Hoffmann-La Roche AG $84.84 04/25/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654616
Principal investigator 1 F. Hoffmann-La Roche AG $69.00 04/25/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654632
Principal investigator 1 F. Hoffmann-La Roche AG $84.84 04/25/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654641
Principal investigator 1 F. Hoffmann-La Roche AG $69.00 04/25/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654645
Principal investigator 1 F. Hoffmann-La Roche AG $242.00 04/25/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654648
Principal investigator 1 F. Hoffmann-La Roche AG $8,473.00 04/25/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654652
Principal investigator 1 F. Hoffmann-La Roche AG $69.00 04/25/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654660
Principal investigator 1 F. Hoffmann-La Roche AG $300.00 04/25/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654680
Principal investigator 1 TG Therapeutics, Inc. $2,059.00 04/23/2025 Non-covered Recipient Entity
Hope Neurology MS Center
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226197925
Principal investigator 1 TG Therapeutics, Inc. $4,730.00 04/23/2025 Non-covered Recipient Entity
Hope Neurology MS Center
TG1101-RMS303 An Open Label Extension Study of Ublituximab in Subjects with Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1226197979
Recipient TG Therapeutics, Inc. $499.50 04/21/2025 Covered Recipient Physician RMS301 No dispute reported 06/30/2026 1226200848
Principal investigator 1 Genentech, Inc. $360.00 04/18/2025 Non-covered Recipient Entity
SIBYL WRAY MD NEUROLOGY PC
OCARINA 3 No dispute reported 06/30/2026 1211654955
Principal investigator 1 TG Therapeutics, Inc. $4,002.90 04/17/2025 Non-covered Recipient Entity
Hope Neurology MS Center
TG1101-RMS303 An Open Label Extension Study of Ublituximab in Subjects with Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1226197995
Principal investigator 1 Genentech, Inc. $92.00 04/16/2025 Non-covered Recipient Entity
SIBYL WRAY MD NEUROLOGY PC
Ocrelizumab RMS High Dose Study No dispute reported 06/30/2026 1211655206
Principal investigator 1 Genentech, Inc. $68.00 04/16/2025 Non-covered Recipient Entity
SIBYL WRAY MD NEUROLOGY PC
Evaluation of Fenebrutinib in RMS patients II No dispute reported 06/30/2026 1211655332
Principal investigator 1 GENZYME CORPORATION $4,300.00 04/14/2025 Non-covered Recipient Entity
Sibyl Wray Md Neurology Pc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226152541
Principal investigator 1 TG Therapeutics, Inc. $12,155.82 04/10/2025 Non-covered Recipient Entity
Hope Neurology MS Center
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226197923
Principal investigator 1 Celgene Corporation $3,500.00 04/09/2025 Non-covered Recipient Entity
Hope Neurology, PLLC
A PHASE 3B, MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE IMMUNOLOGICAL RESPONSE TO, AND THE SAFETY OF, THREE PARENTERALLY ADMINISTERED VACCINES IN SUBJECTS WITH RELAPSING REMITTING MULTIPLE SCLEROSIS WHO RECEIVE ORAL OZANIMOD, NON-PEGYLATED INTERFERON-, OR NO DISEASE MODIFYING THERAPY No dispute reported 06/30/2026 1222306301
Principal investigator 1 TG Therapeutics, Inc. $14,404.20 04/08/2025 Non-covered Recipient Entity
Hope Neurology MS Center
TG1101-RMS303 An Open Label Extension Study of Ublituximab in Subjects with Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1226197977
Principal investigator 1 GENZYME CORPORATION $10,744.00 04/07/2025 Non-covered Recipient Entity
Sibyl Wray Md Neurology Pc
An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226152487
Principal investigator 1 Eli Lilly and Company $3,200.00 04/04/2025 Non-covered Recipient Entity
SIBYL WRAY NEUROLOGY PC
AN ADAPTIVE PHASE 2A/2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF LY3541860 COMPARED TO PLACEBO IN SLOWING THE OCCURRENCE OF NEW T1 GADOLINIUM-ENHANCING LESIONS IN ADULT PARTICIPANTS WITH RELAPSING MULTIPLE SCLEROSIS No dispute reported 06/30/2026 1187891700
Principal investigator 1 GENZYME CORPORATION $500.00 04/02/2025 Non-covered Recipient Entity
Sibyl Wray Md Neurology Pc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226152515
Principal investigator 1 Genentech, Inc. $1,008.00 04/02/2025 Non-covered Recipient Entity
SIBYL WRAY MD NEUROLOGY PC
OCARINA 3 No dispute reported 06/30/2026 1211654968
Principal investigator 1 Genentech, Inc. $1,092.00 04/02/2025 Non-covered Recipient Entity
SIBYL WRAY MD NEUROLOGY PC
Ocrelizumab RMS High Dose Study No dispute reported 06/30/2026 1211655183
Principal investigator 1 Genentech, Inc. $18,018.00 04/02/2025 Non-covered Recipient Entity
SIBYL WRAY MD NEUROLOGY PC
Evaluation of Fenebrutinib in RMS patients II No dispute reported 06/30/2026 1211655308
Recipient TG Therapeutics, Inc. $273.50 04/02/2025 Covered Recipient Physician RMS301 No dispute reported 06/30/2026 1226200842
Recipient TG Therapeutics, Inc. $1,159.23 04/02/2025 Covered Recipient Physician RMS301 No dispute reported 06/30/2026 1226200844
Recipient TG Therapeutics, Inc. $1,076.42 04/02/2025 Covered Recipient Physician RMS302 No dispute reported 06/30/2026 1226200846
Principal investigator 1 Amgen Inc. $22,570.14 04/01/2025 Non-covered Recipient Entity
SIBYL WRAY MD NEUROLOGY PC
A Randomized, Double-blind, Parallel-group Study to Compare Pharmacokinetics, Pharmacodynamics, Clinical Effects, and Safety Between ABP 692 and Ocrevus (Ocrelizumab) in Subjects With Relapsing-remitting Multiple Sclerosis No dispute reported 06/30/2026 1246648169
Principal investigator 1 Genentech, Inc. $5,600.00 04/01/2025 Non-covered Recipient Entity
SIBYL WRAY MD NEUROLOGY PC
Evaluation of Fenebrutinib in RMS patients II No dispute reported 06/30/2026 1211655320
Principal investigator 1 TG Therapeutics, Inc. $7,929.00 03/31/2025 Non-covered Recipient Entity
Hope Neurology MS Center
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226197907
Principal investigator 1 TG Therapeutics, Inc. $14,180.00 03/31/2025 Non-covered Recipient Entity
Hope Neurology MS Center
TG1101-RMS303 An Open Label Extension Study of Ublituximab in Subjects with Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1226197965
Principal investigator 1 GENZYME CORPORATION $64.00 03/24/2025 Non-covered Recipient Entity
Sibyl Wray Md Neurology Pc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226152481
Principal investigator 1 Roche Products Limited $338.00 03/24/2025 Non-covered Recipient Entity
SIBYL WRAY MD NEUROLOGY PC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211655028
Principal investigator 1 Roche Products Limited $338.00 03/24/2025 Non-covered Recipient Entity
SIBYL WRAY MD NEUROLOGY PC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211655032
Principal investigator 1 Roche Products Limited $338.00 03/24/2025 Non-covered Recipient Entity
SIBYL WRAY MD NEUROLOGY PC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211655035
Principal investigator 1 Roche Products Limited $338.00 03/24/2025 Non-covered Recipient Entity
SIBYL WRAY MD NEUROLOGY PC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211655051
Principal investigator 1 Roche Products Limited $338.00 03/24/2025 Non-covered Recipient Entity
SIBYL WRAY MD NEUROLOGY PC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211655056
Principal investigator 1 Roche Products Limited $338.00 03/24/2025 Non-covered Recipient Entity
SIBYL WRAY MD NEUROLOGY PC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211655065
Principal investigator 1 Roche Products Limited $338.00 03/24/2025 Non-covered Recipient Entity
SIBYL WRAY MD NEUROLOGY PC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211655069
Principal investigator 1 F. Hoffmann-La Roche AG $2,874.00 03/21/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654396
Principal investigator 1 F. Hoffmann-La Roche AG $242.00 03/21/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654430
Principal investigator 1 F. Hoffmann-La Roche AG $693.00 03/21/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654450
Principal investigator 1 Genentech, Inc. $3,313.00 03/21/2025 Non-covered Recipient Entity
SIBYL WRAY MD NEUROLOGY PC
OCARINA 3 No dispute reported 06/30/2026 1211654963
Principal investigator 1 Genentech, Inc. $235.00 03/21/2025 Non-covered Recipient Entity
SIBYL WRAY MD NEUROLOGY PC
Evaluation of Fenebrutinib in RMS patients II No dispute reported 06/30/2026 1211655324
Principal investigator 1 Genentech, Inc. $433.00 03/20/2025 Non-covered Recipient Entity
SIBYL WRAY MD NEUROLOGY PC
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211655195
Principal investigator 1 Genentech, Inc. $4,284.00 03/20/2025 Non-covered Recipient Entity
SIBYL WRAY MD NEUROLOGY PC
Ocrelizumab RMS High Dose Study No dispute reported 06/30/2026 1211655198
Principal investigator 1 TG Therapeutics, Inc. $3,516.00 03/20/2025 Non-covered Recipient Entity
Hope Neurology MS Center
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226197921
Principal investigator 1 TG Therapeutics, Inc. $10,039.00 03/20/2025 Non-covered Recipient Entity
Hope Neurology MS Center
TG1101-RMS303 An Open Label Extension Study of Ublituximab in Subjects with Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1226197975
Principal investigator 1 GENZYME CORPORATION $17,600.00 03/17/2025 Non-covered Recipient Entity
Sibyl Wray Md Neurology Pc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226152399
Principal investigator 1 GENZYME CORPORATION $1,600.00 03/17/2025 Non-covered Recipient Entity
Sibyl Wray Md Neurology Pc
A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226152462
Principal investigator 1 F. Hoffmann-La Roche AG $125.00 03/12/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654384
Principal investigator 1 F. Hoffmann-La Roche AG $69.00 03/12/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654388
Principal investigator 1 F. Hoffmann-La Roche AG $125.00 03/12/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654404
Principal investigator 1 F. Hoffmann-La Roche AG $500.00 03/12/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654408
Principal investigator 1 F. Hoffmann-La Roche AG $69.00 03/12/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654412
Principal investigator 1 F. Hoffmann-La Roche AG $69.00 03/12/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654417
Principal investigator 1 F. Hoffmann-La Roche AG $69.00 03/12/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654420
Principal investigator 1 F. Hoffmann-La Roche AG $84.84 03/12/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654423
Principal investigator 1 F. Hoffmann-La Roche AG $156.00 03/12/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654445
Principal investigator 1 F. Hoffmann-La Roche AG $300.00 03/12/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654474
Principal investigator 1 F. Hoffmann-La Roche AG $20.25 03/12/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654483
Principal investigator 1 F. Hoffmann-La Roche AG $1,000.00 03/12/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654490
Principal investigator 1 F. Hoffmann-La Roche AG $69.00 03/12/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654520
Principal investigator 1 Genentech, Inc. $25.00 03/12/2025 Non-covered Recipient Entity
SIBYL WRAY MD NEUROLOGY PC
Evaluation of Fenebrutinib in RMS patients II No dispute reported 06/30/2026 1211655329
Principal investigator 1 SANOFI US SERVICES INC. $10,673.60 03/10/2025 Non-covered Recipient Entity
Paradigm Clinical Research Centers, Inc
A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1226149021
Principal investigator 1 TG Therapeutics, Inc. $5,337.20 03/10/2025 Non-covered Recipient Entity
Hope Neurology MS Center
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226197985
Principal investigator 1 TG Therapeutics, Inc. $11,719.00 03/05/2025 Non-covered Recipient Entity
Hope Neurology MS Center
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226197919
Principal investigator 1 TG Therapeutics, Inc. $1,364.00 03/05/2025 Non-covered Recipient Entity
Hope Neurology MS Center
TG1101-RMS303 An Open Label Extension Study of Ublituximab in Subjects with Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1226197973
Principal investigator 1 GENZYME CORPORATION $214.00 03/04/2025 Non-covered Recipient Entity
Sibyl Wray Md Neurology Pc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226152503
Principal investigator 1 Celgene Corporation $11,508.90 02/28/2025 Non-covered Recipient Entity
Hope Neurology, PLLC
A Multicenter, Longitudinal, Open-Label, Single-Arm Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated with Ozanimod (RPC-1063) No dispute reported 06/30/2026 1222306231
Principal investigator 1 Novartis Pharmaceuticals Corporation $585,023.33 02/28/2025 Non-covered Recipient Entity
SIBYL WRAY MD NEUROLOGY PC
A Randomized, Open Label, Multi-center, Active-comparator Study to Assess Efficacy, Safety & Tolerability of Ofatumumab 20mg sc Monthly Versus Continued Current Therapy in Relapsing-remitting Multiple Sclerosis After Elevation of Serum Neurofilament Light No dispute reported 06/30/2026 1190300097
Principal investigator 1 TG Therapeutics, Inc. $6,217.30 02/28/2025 Non-covered Recipient Entity
Hope Neurology MS Center
TG1101-RMS303 An Open Label Extension Study of Ublituximab in Subjects with Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1226197963
Principal investigator 1 TG Therapeutics, Inc. $21,500.00 02/28/2025 Non-covered Recipient Entity
Hope Neurology MS Center
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198095
Principal investigator 1 TG Therapeutics, Inc. $617.00 02/25/2025 Non-covered Recipient Entity
Hope Neurology MS Center
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226197917
Principal investigator 1 GENZYME CORPORATION $5,615.00 02/24/2025 Non-covered Recipient Entity
Sibyl Wray Md Neurology Pc
A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226152434
Principal investigator 1 GENZYME CORPORATION $59.64 02/24/2025 Non-covered Recipient Entity
Sibyl Wray Md Neurology Pc
An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226152444
Principal investigator 1 GENZYME CORPORATION $2,750.00 02/24/2025 Non-covered Recipient Entity
Sibyl Wray Md Neurology Pc
An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226152455
Recipient Genentech, Inc. $13,936.00 02/20/2025 Covered Recipient Physician Ocrelizumab RMS High Dose Study No dispute reported 06/30/2026 1211538941
Principal investigator 1 TG Therapeutics, Inc. $29,020.00 02/20/2025 Non-covered Recipient Entity
Hope Neurology MS Center
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226197915
Principal investigator 1 TG Therapeutics, Inc. $7,603.50 02/20/2025 Non-covered Recipient Entity
Hope Neurology MS Center
TG1101-RMS303 An Open Label Extension Study of Ublituximab in Subjects with Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1226197971
Principal investigator 1 F. Hoffmann-La Roche AG $693.00 02/19/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654400
Principal investigator 1 F. Hoffmann-La Roche AG $242.00 02/19/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654425
Principal investigator 1 F. Hoffmann-La Roche AG $300.00 02/19/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654434
Principal investigator 1 F. Hoffmann-La Roche AG $500.00 02/19/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654438
Principal investigator 1 F. Hoffmann-La Roche AG $28.71 02/19/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654442
Principal investigator 1 F. Hoffmann-La Roche AG $31.92 02/19/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654454
Principal investigator 1 F. Hoffmann-La Roche AG $39.00 02/19/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654459
Principal investigator 1 F. Hoffmann-La Roche AG $1,000.00 02/19/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654465
Principal investigator 1 F. Hoffmann-La Roche AG $8,473.00 02/19/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654479
Principal investigator 1 F. Hoffmann-La Roche AG $69.00 02/19/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654496
Principal investigator 1 F. Hoffmann-La Roche AG $156.00 02/19/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654505
Principal investigator 1 Novartis Pharmaceuticals Corporation $90,497.51 02/19/2025 Non-covered Recipient Entity
SIBYL WRAY MD NEUROLOGY PC
A Pilot Open-Label, Randomized, Multi-Center, Parall el-Arm, of Acute vs Delay Ofatumumab Treatment d uring an Acute Multiple Sclerosis Relapse No dispute reported 06/30/2026 1190304725
Principal investigator 1 GENZYME CORPORATION $1,250.03 02/18/2025 Non-covered Recipient Entity
Sibyl Wray Md Neurology Pc
An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226152477
Principal investigator 1 GENZYME CORPORATION $203.00 02/18/2025 Non-covered Recipient Entity
Sibyl Wray Md Neurology Pc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226152509
Recipient Genentech, Inc. $2,800.00 02/18/2025 Covered Recipient Physician Evaluation of Fenebrutinib in RMS patients II No dispute reported 06/30/2026 1211538970
Recipient Genentech, Inc. $65.00 02/18/2025 Covered Recipient Physician Evaluation of Fenebrutinib in RMS patients II No dispute reported 06/30/2026 1211538988
Recipient Genentech, Inc. $14,444.00 02/14/2025 Covered Recipient Physician A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211538954
Recipient Genentech, Inc. $121.00 02/13/2025 Covered Recipient Physician A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211538959
Principal investigator 1 TG Therapeutics, Inc. $7,369.00 02/11/2025 Non-covered Recipient Entity
Hope Neurology MS Center
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226197913
Principal investigator 1 GENZYME CORPORATION $8,650.00 02/10/2025 Non-covered Recipient Entity
Sibyl Wray Md Neurology Pc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226152384
Recipient Genentech, Inc. $9,051.00 02/07/2025 Covered Recipient Physician Evaluation of Fenebrutinib in RMS patients II No dispute reported 06/30/2026 1211538966
Recipient Genentech, Inc. $68.00 02/07/2025 Covered Recipient Physician Evaluation of Fenebrutinib in RMS patients II No dispute reported 06/30/2026 1211538984
Recipient Genentech, Inc. $12,822.00 02/05/2025 Covered Recipient Physician OCARINA 3 No dispute reported 06/30/2026 1211538929
Principal investigator 1 TG Therapeutics, Inc. $6,429.00 02/01/2025 Non-covered Recipient Entity
Hope Neurology MS Center
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226197911
Principal investigator 1 TG Therapeutics, Inc. $15,610.23 02/01/2025 Non-covered Recipient Entity
Hope Neurology MS Center
TG1101-RMS303 An Open Label Extension Study of Ublituximab in Subjects with Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1226197967
Principal investigator 1 TG Therapeutics, Inc. $10,201.88 02/01/2025 Non-covered Recipient Entity
Hope Neurology MS Center
TG1101-RMS303 An Open Label Extension Study of Ublituximab in Subjects with Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1226197969
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,831.23 01/31/2025 Non-covered Recipient Entity
SIBYL WRAY MD NEUROLOGY PC
A Randomized, Open Label, Multi-center, Active-comparator Study to Assess Efficacy, Safety & Tolerability of Ofatumumab 20mg sc Monthly Versus Continued Current Therapy in Relapsing-remitting Multiple Sclerosis After Elevation of Serum Neurofilament Light No dispute reported 06/30/2026 1190300095
Principal investigator 1 TG Therapeutics, Inc. $18,201.20 01/31/2025 Non-covered Recipient Entity
Hope Neurology MS Center
TG1101-RMS303 An Open Label Extension Study of Ublituximab in Subjects with Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1226197961
Principal investigator 1 TG Therapeutics, Inc. $12,713.00 01/31/2025 Non-covered Recipient Entity
Hope Neurology MS Center
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198093
Recipient Genentech, Inc. $3,317.00 01/28/2025 Covered Recipient Physician OCARINA 3 No dispute reported 06/30/2026 1211538933
Recipient Genentech, Inc. $1,139.00 01/28/2025 Covered Recipient Physician OCARINA 3 No dispute reported 06/30/2026 1211538936
Recipient Genentech, Inc. $92.00 01/28/2025 Covered Recipient Physician Ocrelizumab RMS High Dose Study No dispute reported 06/30/2026 1211538950
Principal investigator 1 TG Therapeutics, Inc. $6,404.64 01/27/2025 Non-covered Recipient Entity
Hope Neurology MS Center
TG1101-RMS303 An Open Label Extension Study of Ublituximab in Subjects with Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1226197991
Principal investigator 1 GENZYME CORPORATION $735.00 01/24/2025 Non-covered Recipient Entity
Sibyl Wray Md Neurology Pc
An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226152394
Principal investigator 1 F. Hoffmann-La Roche AG $242.00 01/22/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654392
Principal investigator 1 F. Hoffmann-La Roche AG $8,473.00 01/22/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654470
Principal investigator 1 F. Hoffmann-La Roche AG $2,680.00 01/22/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654487
Principal investigator 1 F. Hoffmann-La Roche AG $693.00 01/22/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654500
Principal investigator 1 F. Hoffmann-La Roche AG $8,473.00 01/22/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654508
Principal investigator 1 F. Hoffmann-La Roche AG $242.00 01/22/2025 Non-covered Recipient Entity
Sibyl Wray
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211654515
Recipient Genentech, Inc. $232.00 01/22/2025 Covered Recipient Physician Ocrelizumab RMS High Dose Study No dispute reported 06/30/2026 1211538945
Recipient Genentech, Inc. $5,997.00 01/17/2025 Covered Recipient Physician Evaluation of Fenebrutinib in RMS patients II No dispute reported 06/30/2026 1211538979
Principal investigator 1 Novartis Pharmaceuticals Corporation $363,270.82 01/15/2025 Non-covered Recipient Entity
SIBYL WRAY MD NEUROLOGY PC
A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib No dispute reported 06/30/2026 1190304721
Principal investigator 1 GENZYME CORPORATION $2,775.00 01/13/2025 Non-covered Recipient Entity
Sibyl Wray Md Neurology Pc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226152497
Principal investigator 1 Roche Products Limited $338.00 01/09/2025 Non-covered Recipient Entity
SIBYL WRAY MD NEUROLOGY PC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211655039
Principal investigator 1 Roche Products Limited $338.00 01/09/2025 Non-covered Recipient Entity
SIBYL WRAY MD NEUROLOGY PC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211655047
Principal investigator 1 Roche Products Limited $338.00 01/09/2025 Non-covered Recipient Entity
SIBYL WRAY MD NEUROLOGY PC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211655060
Principal investigator 1 Roche Products Limited $338.00 01/09/2025 Non-covered Recipient Entity
SIBYL WRAY MD NEUROLOGY PC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211655074
Recipient Genentech, Inc. $133.00 01/08/2025 Covered Recipient Physician Evaluation of Fenebrutinib in RMS patients II No dispute reported 06/30/2026 1211538962
Recipient Genentech, Inc. $68.00 01/08/2025 Covered Recipient Physician Evaluation of Fenebrutinib in RMS patients II No dispute reported 06/30/2026 1211538975
Principal investigator 1 Novartis Pharmaceuticals Corporation $290,970.23 01/08/2025 Non-covered Recipient Entity
SIBYL WRAY MD NEUROLOGY PC
An Open label Single Arm Multi center Extension Study Evaluating Long term Safety Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1190300093
Recipient Amgen Inc. $32,550.90 01/07/2025 Covered Recipient Physician A Randomized, Double Blind, Parallel Group Study to Compare Pharmacokinetics, Pharmacodynamics, Clinical Effects, and Safety between ABP 692, and Ocrevus (Ocrelizumab) in Subjects with Relapsing Remitting Multiple Sclerosis No dispute reported 06/30/2026 1246637258
Principal investigator 1 Novartis Pharmaceuticals Corporation $28,981.00 01/07/2025 Non-covered Recipient Entity
SIBYL WRAY MD NEUROLOGY PC
A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib No dispute reported 06/30/2026 1190300087
Principal investigator 1 Novartis Pharmaceuticals Corporation $140,470.45 01/07/2025 Non-covered Recipient Entity
SIBYL WRAY MD NEUROLOGY PC
AGNOS: An 18-month, Open-label, Multi-Center Study to Assess the Effect of Ofatumumab 20mg SC Monthly in Treatment Nave, Very Early Relapsing Remitting Multiple Sclerosis Patients Benchmarked Against Healthy Controls on Select Outcomes No dispute reported 06/30/2026 1190304727
Principal investigator 1 GENZYME CORPORATION $890.00 01/06/2025 Non-covered Recipient Entity
Sibyl Wray Md Neurology Pc
A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226152520
Principal investigator 1 GENZYME CORPORATION $310.00 01/06/2025 Non-covered Recipient Entity
Sibyl Wray Md Neurology Pc
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226152527
Principal investigator 1 TG Therapeutics, Inc. $12,861.60 01/03/2025 Non-covered Recipient Entity
Hope Neurology MS Center
TG1101-RMS303 An Open Label Extension Study of Ublituximab in Subjects with Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1226197959
Principal investigator 1 TG Therapeutics, Inc. $10,112.00 01/02/2025 Non-covered Recipient Entity
Hope Neurology MS Center
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226197909
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,383,338.02 01/01/2025 Non-covered Recipient Entity
SIBYL WRAY MD NEUROLOGY PC
An Open label Single Arm Multi center Extension Study Evaluating Long term Safety Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1190304723